http://purl.org/np/RAD3-dtNzY... RAD3-dtNzY

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-11T07:11:20.835Z

http://purl.org/np/RAD3-dtNzY... RAD3-dtNzY

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-11T07:11:20.835226

Elif Ozkan

2022-10-11T07:11:20.835Z

http://purl.org/np/RAD3-dtNzY... RAD3-dtNzY

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

TNKase® (Tenecteplase) is indicated for use in the reduction of mortality associated with acute myocardial infarction (AMI) Treatment should be initiated as soon as possible after the onset of AMI symptoms, according to the drug's manufacturer. The drug is available in the US for $1,000 in the U.S. and Europe for $2,000.

Elif Ozkan

2022-10-11T07:11:20.835Z